Cencora (COR) – Research Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Cencora (NYSE: COR) recently:

• 8/11/2026 – Cencora had its price target raised by Wells Fargo & Company from $331.00 to $395.00. They now have an “overweight” rating on the stock.
• 8/8/2026 – Cencora was upgraded by Wall Street Zen from “hold” to “buy”.
• 8/7/2026 – Cencora had its price target raised by Morgan Stanley from $342.00 to $346.00. They now have an “overweight” rating on the stock.
• 8/7/2026 – Cencora had its price target raised by JPMorgan Chase & Co. from $382.00 to $390.00. They now have an “overweight” rating on the stock.
• 8/6/2026 – Cencora was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 8/6/2026 – Cencora was given a new $370.00 price target by Robert W. Baird.
• 8/6/2026 – Cencora had its price target raised by UBS Group AG from $412.00 to $430.00. They now have a “buy” rating on the stock.
• 8/6/2026 – Cencora had its “outperform” rating reaffirmed by Evercore Inc. They now have a $350.00 price target on the stock.
• 8/6/2026 – Cencora had its “buy” rating reaffirmed by Citigroup Inc..
• 6/30/2026 – Cencora was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.
• 6/24/2026 – Cencora had its price target raised by Bank of America Corporation from $280.00 to $285.00. They now have a “neutral” rating on the stock.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Friday, August 14th will be given a $0.60 dividend. The ex-dividend date is Friday, August 14th. This represents a $2.40 annualized dividend and a yield of 0.8%. Cencora’s payout ratio is presently 17.83%.

Insider Buying and Selling at Cencora

In other news, Director Lauren M. Tyler bought 550 shares of the business’s stock in a transaction dated Monday, June 22nd. The shares were purchased at an average price of $270.23 per share, for a total transaction of $148,626.50. Following the completion of the acquisition, the director owned 4,359 shares of the company’s stock, valued at approximately $1,177,932.57. This trade represents a 14.44% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 0.38% of the company’s stock.

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.